[go: up one dir, main page]

BR9510554A - Use of mch-ii binding molecules and / or imitation molecules for the prevention and / or treatment of inflammatory diseases - Google Patents

Use of mch-ii binding molecules and / or imitation molecules for the prevention and / or treatment of inflammatory diseases

Info

Publication number
BR9510554A
BR9510554A BR9510554A BR9510554A BR9510554A BR 9510554 A BR9510554 A BR 9510554A BR 9510554 A BR9510554 A BR 9510554A BR 9510554 A BR9510554 A BR 9510554A BR 9510554 A BR9510554 A BR 9510554A
Authority
BR
Brazil
Prior art keywords
molecules
mch
imitation
prevention
treatment
Prior art date
Application number
BR9510554A
Other languages
Portuguese (pt)
Inventor
Roger Pascal Lauener
Original Assignee
Om Lab Sa
Deutsche Om Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Lab Sa, Deutsche Om Arzneimittel Gmbh filed Critical Om Lab Sa
Publication of BR9510554A publication Critical patent/BR9510554A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
BR9510554A 1994-12-23 1995-12-27 Use of mch-ii binding molecules and / or imitation molecules for the prevention and / or treatment of inflammatory diseases BR9510554A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203755 1994-12-23
PCT/EP1995/005164 WO1996020215A2 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
BR9510554A true BR9510554A (en) 1999-06-29

Family

ID=8217495

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9510554A BR9510554A (en) 1994-12-23 1995-12-27 Use of mch-ii binding molecules and / or imitation molecules for the prevention and / or treatment of inflammatory diseases

Country Status (11)

Country Link
EP (1) EP0800534A2 (en)
JP (1) JPH10511652A (en)
CN (1) CN1171117A (en)
AU (1) AU4347696A (en)
BR (1) BR9510554A (en)
CA (1) CA2208233A1 (en)
CZ (1) CZ186897A3 (en)
HU (1) HUT77468A (en)
PL (1) PL320922A1 (en)
SK (1) SK80697A3 (en)
WO (1) WO1996020215A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
JPH11507843A (en) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー Soluble divalent and multivalent heterodimer analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
DK1404367T3 (en) * 2001-07-02 2010-12-13 Aimsco Ltd Use of polyclonal anti-HIV goat serum as a therapeutic agent
EP1469882B1 (en) * 2002-01-28 2010-08-25 Aimsco Limited Treatment of nervous system diseases with goat serum
ES2232273B1 (en) * 2003-03-21 2006-07-16 Jose Manuel Fernandez-Real Lemos NEW THERAPEUTIC APPLICATIONS OF GLUCOPROTEIN CD14S.
AU2004241069B2 (en) * 2003-05-15 2010-09-09 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) * 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
GB8310403D0 (en) * 1983-04-18 1983-05-25 Mach B F Cotransformed mouse cells
JPS6225994A (en) * 1985-05-30 1987-02-03 ジエネテイツク　システムズ　コ−ポレイシヨン Monoclonal antibody for separating hla type
JPS63275526A (en) * 1987-05-03 1988-11-14 Hiroshi Okajima Hiv virus neutralizing antibody
FR2658197B1 (en) * 1990-02-14 1992-05-22 Inst Nat Sante Rech Med RESTRICTED MONOCLONAL ANTIBODIES RECOGNIZING A PEPTIDE ASSOCIATED WITH A MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN - APPLICATIONS TO DIAGNOSIS AND TREATMENT.
DE4029227A1 (en) * 1990-09-14 1992-03-19 Imtox Gmbh MEDICINAL PRODUCT CONTAINING CD14
WO1993010220A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Soluble mhc molecules and their uses
WO1993019772A1 (en) * 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
DE69332268T2 (en) * 1992-10-15 2003-08-14 Toray Industries, Inc. METHOD FOR PRODUCING RECOMBINANT MHCII PROTEIN IN MICROORGANISMS
WO1994028025A1 (en) * 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Also Published As

Publication number Publication date
CZ186897A3 (en) 1998-03-18
WO1996020215A3 (en) 1996-10-10
JPH10511652A (en) 1998-11-10
CA2208233A1 (en) 1996-07-04
WO1996020215A2 (en) 1996-07-04
AU4347696A (en) 1996-07-19
HUT77468A (en) 1998-05-28
PL320922A1 (en) 1997-11-10
CN1171117A (en) 1998-01-21
EP0800534A2 (en) 1997-10-15
SK80697A3 (en) 1997-12-10

Similar Documents

Publication Publication Date Title
BR9504072A (en) Pharmaceutical composition methods for the treatment of atherosclerosis hypercholesterolemia and kit
PT1083889E (en) TETRA-HYDROFOLANTALINE COMPOUNDS AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
BR9711530A (en) Combination of therapy for the treatment of psychoses
FI970920L (en) Triphenylethylenes for use in the prevention and treatment of osteoporosis
FI951801L (en) CTLA4 molecules and IL4-binding molecules and their use
FI963696A7 (en) Gel for treating skin diseases and disinfecting the skin
DE69518919D1 (en) AUTOANTIBODY COMPOSITION FOR TUMOR TREATMENT AND PREVENTION
PT966436E (en) ARILSULFONAMIDES AND ANALOGS AND THEIR APPLICATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
FI952721A7 (en) Substance for the treatment of hepatobiliary diseases
FI971969A0 (en) Compositions and method of use for the treatment of hemorrhoids
FI963252A7 (en) Novel opioid peptides for the treatment of pain and their use
BR9505368A (en) Cosmetic or dermatogogic composition water-in-oil
BR9504385A (en) Compounded pharmaceutical composition methods for inhibiting binding and for treating inflammatory disorders
ID18679A (en) USE OF FURTHER THERAPY
PT752870E (en) USING MYCOBACTERIUM FOR THE TREATMENT OF TUMORS
FI950440L (en) Electrodialysis treatment
BR9510554A (en) Use of mch-ii binding molecules and / or imitation molecules for the prevention and / or treatment of inflammatory diseases
BR9709846A (en) Liquid filter and filter
FI951060A7 (en) Formulations and treatment methods
FI964936L (en) Benzopyrans and their use as therapeutic agents
DE59707096D1 (en) Hair treatment agent for setting the hair
FI964227A7 (en) Heparin binding protein for the treatment of septicemia and methods for its preparation
NO965247D0 (en) Use of cross-linked hemoglobin in the treatment of subarakuoid hemorrhage
FI963264A7 (en) Agent for the prevention and treatment of thromboxane A2-mediated diseases
IL115505A0 (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]